CALCITONIN IN THE PREVENTION AND TREATMENT OF OSTEOPOROSIS
CALCITONIN IN THE PREVENTION AND TREATMENT OF OSTEOPOROSIS
复制标题
DOI：
10.1007/bf01621908
复制
发表时间：
1993-01-01
影响因子：
4
通讯作者：
CHESTNUT, CH
中科院分区：
文献类型：
--
作者：
CHESTNUT, CH
The naturally occurring hormone calcitonin is a valued component of therapeutic programs currently available for osteoporosis. Calcitonin inhibits osteoclast-mediated bone resorption by decreasing osteoclast function, and possibly by reducing the osteoclast population through diminishing the differentiation of osteoclast progenitor cells. Whether calcitonin deficiency, or deficiency of calcitonin secretory reserve, contributes to the etiology of postmenopausal osteoporosis is currently unclear, but seems unlikely.Calcitonin efficacy in osteoporosis, particularly of the postmenopausal type, has been verified in numerous clinical trials over the past 15 years. The majority of the data on calcitonin therapy is derived from studies performed with the synthetic salmon congener [1]; human calcitonin has also proven effective in at least one prophylactic study [2]. The ability of parenterally injected salmon calcitonin to provide beneficial effects on bone mass at multiple sites throughout the skeleton (including the spine, hip, total skeleton and possibly wrist) has been well documented for durations of up to 2 years in populations with established osteoporosis fractures. In such studies bone mass at a number of measured sites actually increases slightly, but this is probably due to a transient'uncoupling'of normal'coupling'mechanisms (a decrease in bone resorption without a corresponding decrease in bone formation) rather than to a primary increase in bone formation.
